CDK4 and breast carcinoma: Ongoing and future clinical trials will evaluate the potential and applicability of combining endocrine therapy with growth factor inhibitors or CDK4/6 inhibitors to overcome intrinsic resistance and prevent or delay acquired resistance in patients with ER+/HER2+ breast cancer.